21 December 2020: Clinical Research
Retrospective Study of Clinical Features of COVID-19 in Inpatients and Their Association with Disease Severity
Hao Wang 1AE* , Yang Xing 2CDEF* , Xiaohong Yao 3BD , Yang Li 1C , Jietao Huang 1CD , Jun Tang 1BF , Shasha Zhu 1CD , Ying Zhang 1EG* , Jun Xiao 1G*DOI: 10.12659/MSM.927674
Med Sci Monit 2020; 26:e927674
Table 2 Laboratory indices of patients with COVID-19.
| Normal range | Total (N=61) | Common group (N=37) | Severe group (N=24) | P value | |
|---|---|---|---|---|---|
| White blood count, ×10/L | 4–10 | 5.4 (4.05–6.9) | 5.3 (4.19–7.02) | 5.4 1(3.68–6.77) | 0.74 |
| 14 (23.0%) | 6 (16.2%) | 8 (33.3%) | 0.12 | ||
| ≥4 | 47 (77.0%) | 31 (83.8%) | 16 (66.7%) | ||
| Neutrophil count, ×10/L | 1.8–6.3 | 3.39 (2.52–4.62) | 3.28 (2.46–4.24) | 4.07 (2.75–5.54) | 0.218 |
| 1 (1.6%) | 0 | 1 (4.2%) | 0.168 | ||
| ≥1.8 | 60 (98.4%) | 37 (100.0%) | 23 (95.8%) | ||
| Lymphocyte count, ×10/L | 1.1–3.2 | 1.28 (0.84–1.6) | 1.41 (1.19–1.78) | 0.91 (0.48–1.24) | |
| 23 (37.7%) | 7 (18.9%) | 16 (66.7%) | |||
| ≥1.1 | 38 (62.3%) | 30 (81.1%) | 8 (33.3%) | ||
| Monocyte count, ×10/L | 0.1–0.6 | 0.39 (0.28–0.52) | 0.39 (0.32–0.52) | 0.38 (0.2–0.52) | 0.337 |
| Red blood cell distribution width, % | 11–16 | 12.6 (12.2–14.15) | 12.4 (12.2–14.25) | 12. 7(12.33–13.1) | 0.848 |
| Platelet count, ×10/L | 125–350 | 206 (157.5–251.5) | 217 (183.5–252) | 163.5 (133.25–248.25) | 0.066 |
| 5 (8.2%) | 1 (2.7%) | 4 (16.7%) | 0.052 | ||
| ≥125 | 56 (91.8%) | 36 (97.3%) | 20 (83.3%) | ||
| Mean platelet volume, fl | 9–13 | 10.1 (9.05–10.95) | 10.1(9–10.8) | 10.4(9.65–11.18) | 0.243 |
| Albumin, g/L | 40–55 | 37.8 (34.4–40.68) | 38.39(35.85–41.09) | 35(33.55–40.17) | 0.046 |
| 40 (66.7%) | 23 (62.2%) | 17 (73.9%) | 0.348 | ||
| ≥40 | 20 (33.3%) | 14 (37.8%) | 6 (26.1%) | ||
| Aspartate aminotransferase, U/L | 15–40 | 27.43 (19.67–34.69) | 21.4(15.04–29.69) | 31.57(25.69–40.06) | 0.014 |
| >40 | 5 (16.7%) | 2 (12.5%) | 3 (21.4%) | 0.513 | |
| ≤40 | 25 (83.3%) | 14 (87.5%) | 11 (78.6%) | ||
| Urea, mmol/L | 3.1–8 | 3.86 (2.9–5.1) | 3.33 (2.64–4.06) | 4.93 (4–6.4) | |
| >8 | 5 (8.3%) | 0 | 5 (20.8%) | 0.002 | |
| ≤8 | 55 (91.7%) | 36 (100.0%) | 19 (79.2%) | ||
| Creatinine, μmol/L | 57–97 | 63.63 (50.8–77.8) | 59.55 (44.32–71.52) | 71.5 (56.6–83.68) | 0.01 |
| >97 | 4 (6.7%) | 1 (2.8%) | 3 (12.5%) | 0.141 | |
| ≤97 | 56 (93.3%) | 35 (97.2%) | 21 (87.5%) | ||
| D-dimer, ng/mL | 0–1.5 | 0.42 (0.15–0.84) | 0.44 (0.18–0.84) | 0.4 (0.11–1.05) | 0.527 |
| Prothrombin time, s | 10.5–13.5 | 11.5 (10.6–12.3) | 11.1 (10.6–11.8) | 12.1 (11.05–15.7) | 0.003 |
| >13.5 | 19 (32.2%) | 7 (20.0%) | 12 (50.0%) | 0.015 | |
| ≤13.5 | 40 (67.8%) | 28 (80.0%) | 12 (50.0%) | ||
| Creatine kinase isoenzymes, U/L | 0–24 | 9.9 (7–13.25) | 9.25 (6.53–11.89) | 11.82 (7–19) | 0.079 |
| Lactate dehydrogenase, U/L | 120–250 | 195 (166.75–303.15) | 176.02 (162.5–204.93) | 253.94 (196.5–352.12) | 0.001 |
| >250 | 16(29.6%) | 5 (15.6%) | 11 (50.0%) | 0.007 | |
| ≤250 | 38 (70.4%) | 27 (84.4%) | 11 (50.0%) | ||
| C-reactive protein, mg/L | 0–5 | 15.56 (0.9–49.22) | 2.08 (0.54–22.66) | 40.9 (9.7–70.58) | |
| >5 | 34 (57.6%) | 15 (41.7%) | 19 (82.6%) | 0.002 | |
| ≤5 | 25 (42.4%) | 21 (58.3%) | 4 (17.4%) | ||
| Procalcitonin, μg/L | 0–0.5 | 0.08 (0.05–0.23) | 0.07 (0.05–0.18) | 0.1 (0.05–0.27) | 0.557 |
| >0.5 | 6 (11.3%) | 2 (6.3%) | 4 (19.0%) | 0.155 | |
| ≤0.5 | 47 (88.7%) | 30 (93.7%) | 17 (81.0%) | ||
| Neutrophil-to-lymphocyte ratio, NLR | NA (not available) | 2.88 (1.94–5.05) | 2.34 (1.55–3.86) | 4.72 (2.89–6.81) | |
| Lymphocyte-to-monocyte ratio, LMR | NA | 3.2 (2.25–4.24) | 3.6 (2.89–4.45) | 2.71 (1.84–3.19) | 0.004 |
| Platelet-to-lymphocyte ratio, PLR | NA | 170.07 (130.18–225.03) | 152.78 (122.06–185.18) | 213.49 (151.08–356.13) | 0.004 |
| Mean platelet volume to lymphocyte ratio, MPVLR | NA | 7.65 (5.97–13.3) | 7.03 (5.7–7.98) | 12.61 (7.33–21) | |
| C-reactive protein to albumin ratio, CAR | NA | 0.43 (0.02–1.28) | 0.06 (0.01–0.6) | 1.09 (0.07–2.03) | 0.001 |